#IncannexHealthcare is pleased to report positive data from its Phase 2 #clinicaltrial of PSX-001 (formerly Psi-GAD), a psilocybin-assisted #psychotherapy treatment for Generalised Anxiety Disorder (GAD). Read more: https://t.co/kd1SIn9znG $IXHL #ClinicalTrials #IXHL

IHL-42X's positive topline results from its Phase 2 #clinicaltrial confirm statistically significant & clinically meaningful improvements across key endpoints, reinforcing its potential as a best-in-class therapy for patients. Learn more here: https://t.co/94NarLB9WJ $IXHL

#IncannexHealthcare’s President and CEO, Joel Latham, discusses both his and the $IXHL's extreme dedication to finding ways to shorten the path to commercialization for the company’s game changing programs Listen to his conversation with @BenMComer here: https://t.co/3tnh0ABlUM

$IXHL's President and CEO, Joel Latham, joined the @Xtalks Life Science Podcast to discuss how #IXHL is advancing #cannabinoid and psychedelic therapies for chronic conditions like #sleepapnea, #rheumatoidarthritis, and anxiety disorders. Listen here:

$IXHL's President & CEO, Joel Latham, spoke with @BenMComer of the Business of Biotech Podcast about developing #cannabinoid and psychedelic combination therapies for #sleepapnea, #rheumatoidarthritis, and generalized anxiety disorder. Listen here: https://t.co/LVlvMcOHy6 #IXHL

$IXHL's Head of Clinical Operations, Natalie May, brings 20+ years of experience managing clinical research programs in the #biopharma and #medicaldevice industries. She leads clinical research for #IXHL’s product development programs. Learn more here: https://t.co/qWfSFhnPQQ

#IncannexHealthcare’s President and CEO, Joel Latham, recently spoke with @GaurVatsala of @InvezzPortal about how despite IHL-42X’s demonstration of tangible benefits for patients, the market has to reflect $IXHL's pipeline progress. Read more: https://t.co/9DwG5vNsok #IXHL

Check out @PsychTimes latest coverage of #IncannexHealthcare’s positive data from its phase 2 #clinicaltrial of PSX-001, a psilocybin-assisted #psychotherapy treatment for generalized anxiety disorder. Read the coverage here: https://t.co/tvakTcvALS #IXHL #ClinicalTrials $IXHL

#IncannexHealthcare announced that its Board of Directors has authorized a share repurchase program for up to $20 million of $IXHL's outstanding shares of common stock. Read the full press release here: https://t.co/chN997XXZG #IXHL

#IncannexHealthcare’s IHL-42X #ObstructiveSleepApnea (OSA) #clinicaltrial topline results and overall study were recently covered by @HealioPulm. Check out the full article here: https://t.co/qAyfxNkNnD #IXHL #ClinicalTrials $IXHL @GoHealio

$IXHL's #RePOSA Phase 2 #clinicaltrial demonstrated clear statistically and clinically significant improvements across multiple key endpoints for patients receiving IHL-42X compared to placebo, highlighting its potential to reduce OSA severity. Read more:

#IncannexHealthcare announces new patient-reported outcome findings from a subset of participants in its #RePOSA Phase 2 #clinicaltrial of IHL-42X for the treatment of #obstructivesleepapnoea (OSA). Read more: https://t.co/Bk0VRMKAJC $IXHL #ClinicalTrials #IXHL #ClinicalTrials

In response to recent questions it received from a number of its stockholders, $IXHL announces that it does not presently intend to use the full capacity available under its at the market offering program (the “ATM”) in the near-term. Press release here: https://t.co/9yKv7mLBH8

#IncannexHealthcare is excited to share positive topline results from its #RePOSA Phase 2 #clinicaltrial evaluating IHL-42X, a novel oral drug candidate for #obstructivesleepapnea (OSA). Read more here: https://t.co/l0d95y8YtT #ClinicalTrials #SleepApnea #Incannex $IXHL #IXHL

#IncannexHealthcare announces the appointment of Charlene E. Gamaldo, M.D., to its IHL-42X #ObstructiveSleepApnea (OSA) Clinical Advisory Board. Read our full press release here: https://t.co/UUOtRH9Cva $IXHL #Neurology #IXHL @HopkinsMedicine #SleepApnea

#IncannexHealthcare is dedicated to developing and delivering innovative medicines for those that have chronic diseases with unmet needs. $IXHL encourages physicians and patients interested in our #investigationaltherapy #clinicaltrials to visit our site: https://t.co/hAWGVyIsxX

#IncannexHealthcare is on a mission to leverage smart drug combinations and purposeful partnerships to develop a new standard of care for each of our programs using #cannabinoid combination-based medicines for clinicians and patients. Learn more: https://t.co/qWfSFhnPQQ $IXHL

#IncannexHealthcare is currently developing IHL-675A, an oral fixed-dose combination of a synthetic cannabidiol and hydroxychloroquine sulfate, for the treatment of patients with #rheumatoidarthritis (RA). Learn more on our website: https://t.co/zd68YHH2cR $IXHL #IXHL

#IncannexHealthcare welcomes collaborations with partners who share our commitment to addressing unmet medical needs and advancing innovative therapeutics for patients. Together, we can make a meaningful impact in healthcare. Learn more: https://t.co/72TIwCHzr5 $IXHL

Today we’re featuring #IncannexHealthcare’s CSO Mark Bleackley, Ph.D. With more than two decades of experience in industry and academic research, Dr. Bleackley is responsible for R&D strategy and operations at #Incannex. Learn more: https://t.co/o4aPVla8Vb $IXHL